Risk-assessment tools for venous thromboembolism
| . | IMPEDE –VTE21 . | SAVED22 . | PRISM23 . |
|---|---|---|---|
| Population | VACCR, n = 4446—validated in SEER | SEER, n = 2397 Goal: to define IMiD-related risk of thrombosis—validated in VHA database | Consecutive patients Cleveland Clinic, n = 783—validated in CUIMC Multiple Myeloma and Amyloidosis Program |
| Risk factors | |||
| VTE history | +5 | +3 | +8 |
| Dexamethasone | |||
| High dose (>160 mg/mo) | +4 | +2 | |
| Low dose | +2 | +1 | |
| IMiDs | +4 | +2 | |
| Fracture pelvic/hip/femur | +4 | ||
| Use of erythropoietin | +1 | ||
| Use of tunneled line/CVC | +2 | ||
| BMI ≥25 | +1 | ||
| Asian/Pacific Islander | −3 | ||
| Asian race | −3 | ||
| Black race | +1 | ||
| Age ≥80 y | +1 | ||
| Surgery within 90 d | +2 | +5 | |
| Existing use of anticoagulant (LMWH or oral anticoagulants) or antiplatelet aggregation drugs (aspirin), either therapeutically or prophylactically | −4 (−3 if prophylactic) | ||
| Abnormal cytogenetics | +2 | ||
| Risk stratification | Low ≤3 | Low ≤1 | Low 0 |
| Intermediate 4-7 | Intermediate 1-6 | ||
| High ≥8 | High ≥2 | High ≥7 | |
| Cumulative incidence of Vte in the first 6 (IMPEDE-VTE and SAVED) or 12 mo (SAVED and PRISM) | Low 3.3% | Low 7%/10% | Low 6.4% |
| Intermediate 8.3% | Intermediate 10.7% | ||
| High 15.2% | High 12%/19% | High 23.8% |
| . | IMPEDE –VTE21 . | SAVED22 . | PRISM23 . |
|---|---|---|---|
| Population | VACCR, n = 4446—validated in SEER | SEER, n = 2397 Goal: to define IMiD-related risk of thrombosis—validated in VHA database | Consecutive patients Cleveland Clinic, n = 783—validated in CUIMC Multiple Myeloma and Amyloidosis Program |
| Risk factors | |||
| VTE history | +5 | +3 | +8 |
| Dexamethasone | |||
| High dose (>160 mg/mo) | +4 | +2 | |
| Low dose | +2 | +1 | |
| IMiDs | +4 | +2 | |
| Fracture pelvic/hip/femur | +4 | ||
| Use of erythropoietin | +1 | ||
| Use of tunneled line/CVC | +2 | ||
| BMI ≥25 | +1 | ||
| Asian/Pacific Islander | −3 | ||
| Asian race | −3 | ||
| Black race | +1 | ||
| Age ≥80 y | +1 | ||
| Surgery within 90 d | +2 | +5 | |
| Existing use of anticoagulant (LMWH or oral anticoagulants) or antiplatelet aggregation drugs (aspirin), either therapeutically or prophylactically | −4 (−3 if prophylactic) | ||
| Abnormal cytogenetics | +2 | ||
| Risk stratification | Low ≤3 | Low ≤1 | Low 0 |
| Intermediate 4-7 | Intermediate 1-6 | ||
| High ≥8 | High ≥2 | High ≥7 | |
| Cumulative incidence of Vte in the first 6 (IMPEDE-VTE and SAVED) or 12 mo (SAVED and PRISM) | Low 3.3% | Low 7%/10% | Low 6.4% |
| Intermediate 8.3% | Intermediate 10.7% | ||
| High 15.2% | High 12%/19% | High 23.8% |
BMI, body mass index; CUIMC, Columbia University Irving Medical Center; CVC, central venous catheter; SEER, Surveillance, Epidemiology, End Results; VACCR, Veterans Administration Central Cancer Registry; VHA, Veterans Health Administration.